Full text is available at the source.
Abstract
Emerging evidence suggests that Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have neuropsychiatric effects.
- GLP-1RAs are linked to potential benefits for conditions such as depression, anxiety, binge eating disorder, cognitive impairment, dementia, and substance use disorders.
- Reported mechanisms for these effects include changes in neuroinflammation, neurotransmitter systems, and pathways related to reward.
- Current evidence is mainly drawn from small and varied studies with short follow-up periods.
- There is a need for larger randomized trials that utilize standardized endpoints related to mental health.
Simplified